Subjects with active infection with signs of SARS-COV-2 at screening visit History of covid-19 based on a previous positive PCR Treatment of active Cytomegalovirus (CMV) infection History of receiving rituximab during the past 6 months History of receiving IVIg during the past 6 months Subjects who have a history of severe allergic reactions (e.g. anaphylaxis) to the study vaccine or any components of the vaccine or any other drugs Subjects who have received any other investigational product within 30 days prior to the screening visit or intend to participate in other clinical studies during this trial History of transplant rejection during the past 30 days Subjects with special circumstances who, may increase the risk of participating in the study or interfering with the evaluation of the primary endpoints of the study according to researcher's opinion

Subjects with active infection with signs of SARS-COV-2 at screening visit History of covid-19 based on a previous positive PCR Treatment of active Cytomegalovirus (CMV) infection History of receiving rituximab during the past 6 months History of receiving IVIg during the past 6 months Subjects who have a history of severe allergic reactions (e.g. anaphylaxis) to the study vaccine or any components of the vaccine or any other drugs Subjects who have received any other investigational product within 30 days prior to the screening visit or intend to participate in other clinical studies during this trial History of transplant rejection during the past 30 days Subjects with special circumstances who, may increase the risk of participating in the study or interfering with the evaluation of the primary endpoints of the study according to researcher's opinion